Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclosporine + omeprazole is a combination of two pharmaceutical agents used for different primary indications. Cyclosporine is an immunosuppressant that acts as a calcineurin inhibitor to suppress T-cell activation and cytokine production by binding to cyclophilin and inhibiting the phosphatase activity of calcineurin. This mechanism prevents the transcription of interleukin-2 and other cytokines critical for T-cell proliferation[4][6]. It is primarily indicated for preventing organ transplant rejection and treating certain autoimmune conditions. Omeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme in gastric parietal cells. This action blocks the final step in gastric acid secretion, leading to reduced stomach acidity[5][8]. Omeprazole is used mainly for gastroesophageal reflux disease (GERD), peptic ulcer disease, Helicobacter pylori eradication regimens, erosive esophagitis due to acid-mediated GERD, and other hypersecretory conditions. When coadministered, there may be pharmacokinetic interactions; omeprazole can alter blood concentrations of cyclosporine in some patients—both increased and decreased levels have been reported. The mechanism behind this interaction remains unclear but may involve effects on hepatic metabolism or absorption[1][2][3]. Clinical studies suggest that standard doses of omeprazole do not significantly affect cyclosporine levels in stable renal transplant patients; however, monitoring may be warranted due to case reports indicating variable effects[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclosporine + omeprazole.